Role of cyclooxygenase-2 in breast cancer
- PMID: 12472107
- DOI: 10.1006/jsre.2002.6532
Role of cyclooxygenase-2 in breast cancer
Abstract
Cyclooxygenase-2 (COX-2), the enzyme that converts arachidonic acid to prostaglandin H2, is expressed in normal brain and kidney, activated macrophages, synoviocytes during inflammation, and malignant epithelial cells. COX-2 expression is stimulated by a number of inflammatory cytokines, growth factors, oncogenes, lipopolysaccharides, and tumor promoters. There is evidence that COX-2 plays a key role in tumorigenesis through stimulating epithelial cell proliferation, inhibiting apoptosis, stimulating angiogenesis, enhancing cell invasiveness, mediating immune suppression, and by increasing the production of mutagens. Results of several studies using mouse models of colon cancer and the results of clinical trials have shown COX-2 to be a useful target for the prevention and treatment of colon cancer. Studies with several other epithelial cancers involving different organ sites, e.g., breast, prostate, bladder, lung, and pancreas, suggest that COX-2 plays an important role in the pathogenesis of these cancers. In this review, we summarize the studies that pertain to the involvement of COX-2 in breast cancer. COX-2 overexpression affects the physiological processes at different organ sites in a similar manner, although specific effectors and targets of COX-2 may differ at different sites. Thus in reviewing the data on the involvement of COX-2 in breast cancer, we have also considered the findings regarding the role of COX-2 in other organ sites. Studies from mouse models of mammary tumorigenesis and from human breast cancer cell lines provide evidence that COX-2 overexpression plays an important role in the pathogenesis of malignant breast cancer in humans. Because of availability of effective and relatively safe COX-2 inhibitors, it should be soon possible to evaluate their effectiveness in the clinic for the prevention and treatment of breast cancer. It is likely that the COX-2 inhibitors will be effective in the treatment regimens involving combination chemotherapies.
Similar articles
-
COX-2 inhibitors for the prevention of breast cancer.J Mammary Gland Biol Neoplasia. 2003 Jan;8(1):31-43. doi: 10.1023/a:1025731204719. J Mammary Gland Biol Neoplasia. 2003. PMID: 14587862 Review.
-
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.Cancer Res. 2002 Mar 15;62(6):1676-81. Cancer Res. 2002. PMID: 11912139
-
Prognostic impact of cyclooxygenase-2 in breast cancer.Clin Breast Cancer. 2004 Feb;4(6):428-33. doi: 10.3816/cbc.2004.n.006. Clin Breast Cancer. 2004. PMID: 15023244 Review.
-
[The clinical significance of expression of cyclooxygenase-2 gene in breast cancer].Zhonghua Yi Xue Za Zhi. 2003 Oct 10;83(19):1661-4. Zhonghua Yi Xue Za Zhi. 2003. PMID: 14642098 Chinese.
-
Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.Prostaglandins Leukot Essent Fatty Acids. 2002 Jan;66(1):13-8. doi: 10.1054/plef.2001.0335. Prostaglandins Leukot Essent Fatty Acids. 2002. PMID: 12051953 Review.
Cited by
-
Celastrol nanoparticles inhibit corneal neovascularization induced by suturing in rats.Int J Nanomedicine. 2012;7:1163-73. doi: 10.2147/IJN.S27860. Epub 2012 Mar 1. Int J Nanomedicine. 2012. PMID: 22419865 Free PMC article.
-
Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategies.Cancers (Basel). 2011 Jun 9;3(2):2597-629. doi: 10.3390/cancers3022597. Cancers (Basel). 2011. PMID: 24212824 Free PMC article.
-
A mechanism underlying the effects of polyunsaturated fatty acids on breast cancer.Int J Mol Med. 2012 Sep;30(3):487-94. doi: 10.3892/ijmm.2012.1022. Epub 2012 Jun 11. Int J Mol Med. 2012. PMID: 22692672 Free PMC article.
-
Functional nsSNPs from carcinogenesis-related genes expressed in breast tissue: potential breast cancer risk alleles and their distribution across human populations.Hum Genomics. 2006 Mar;2(5):287-96. doi: 10.1186/1479-7364-2-5-287. Hum Genomics. 2006. PMID: 16595073 Free PMC article.
-
Effect of cycloxygenase-2 silencing on the malignant biological behavior of MCF-7 breast cancer cells.Oncol Lett. 2014 Oct;8(4):1628-1634. doi: 10.3892/ol.2014.2395. Epub 2014 Jul 30. Oncol Lett. 2014. PMID: 25202381 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials